The carbohydrate-deficient glycoprotein syndromes (CDGS) are genetic, multisystemic diseases characterized by deficiencies in the glycosylation of many secretory glycoproteins, lysosomal enzymes, and possibly cell surface glycoproteins resulting in central nervous system abnormalities and frequent early death by infection. Here we examined whether membranous glycoconjugates of lymphocytes are affected by this disorder. For this, we analyzed cell surface-expressed sialoglycans of Epstein Barr virus (EBV)-transformed B cell lines derived from peripheral B lymphocytes of several patients with CDGS I A. These CDG-LCL (lymphoblastoid cell lines) expressed differentiation markers comparable to those of other EBV-transformed B cell lines. No apparent defects in the gross glycosylation process of defined complex glycosylated proteins such as the surface-expressed major histocompatibility complex class I glycoprotein or secreted immunoglobulin (IgM) were identified. However, using a novel flow cytometric enzyme assay to measure cell surface α2,6 sialylation on live cells we found that CDG-LCL express less α2,6 sialylated glycans in comparison to other EBV-transformed B cell lines. Also, CDG-LCL bound less of the B lymphocyte lectin CD22, specific for α2,6 sialylated lactosamines and known to modulate B cell receptor mediated signaling, as demonstrated by using a soluble CD22-immunoglobulin fusion protein in flow cytometry. CDG-LCL showed stronger surface staining with the monoclonal antibody 1B2 which detects a distinct group of surface-expressed lactosaminyl epitopes. After pretreatment with neuraminidase of Newcastle disease virus (NDVN) it became apparent that in CDG-LCL a significantly larger portion of the 1B2 epitopes was sialylated in α2,3 linkage as compared to other B cell lines. Intracellular α2,6 sialyltransferase activity as well as polymerase chain reaction products specific for four different sialyltransferases did not significantly differ in CDG-LCL as compared to other EBV-B cell lines. Differences in sialylation may be caused by the respective oligosaccharide core structures available for α2,6 or α2,3 sialylation in CDG-LCL. Therefore, lymphocytes derived from CDGS patients have distinct deviations in their surface-expressed lactosaminoglycan structures which may affect functions as exemplified by reduced interactions of CD22 with its ligands.
Introduction
The carbohydrate-deficient glycoprotein syndromes (CDGS) are autosomal recessive, multisystemic diseases characterized by a deficiency of secretory and lysosomal glycoproteins (Stibler et al., 1991; Jaeken et al., 1993a; Winchester et al., 1995) . The diagnosis is usually made by isoelectrofocusing of serum transferrin. Reduced sialylation of transferrin leads to abnormal isoforms with higher isoelectric points (Jaeken et al., 1984; Yamashita et al., 1993a,b) . Also, other serum glycoproteins are abnormal in terms of quantitative expression or in their structural appearance (Jaeken et al., 1993a) . Four different types of CDGS are distinguished (Jaeken et al., 1993a,b; Stibler et al., 1995 Stibler et al., , 1996 . For CDGS III and IV the exact primary cause is not yet defined. The primary defect in CDGS II is a deficiency of the Golgi-enzyme N-acetylglucosaminyltransferase II (Jaeken et al., 1993b; Charuk et al., 1995) . The large majority of patients with a type I serum sialotransferrin pattern have a phosphomannomutase deficiency (type I A) (van Schaftingen and Jaeken, 1995; Jaeken et al., 1997) .
While ample information is available about alterations of serum glycoproteins only few studies have been undertaken to analyze possible defects in cellular glycoproteins of CDGSpatients. Although glycosylation of defined glycoproteins was found to be normal in skin fibroblasts, glycoprotein transport along the secretory pathway seemed to be delayed (Powell et al., 1994; Marquardt et al., 1995) . To our knowledge no further information is available about glycosylation of cell surfaceexpressed glycoproteins in CDGS patients. Although most obvious symptoms of CDGS are based on defects of the nervous system, other organs are equally affected (Jaeken et al., 1993a) . Since many of these patients die during their first years as a consequence of severe infections (Jaeken et al., 1993a) , the immune system may also be deficient in CDGS patients.
Defective glycosylation of major surface receptors may severely influence functions of immune cells as demonstrated by treatment with several glycosylation inhibitors. For instance, treatment with tunicamycin, inhibiting N-glycosylation, blocked the MHC-mediated activity of cytotoxic T lymphocytes. However minor alterations of glycosylation induced by swainsonine or deoxymannojirimycin treatment did not affect antigen presentation of MHC (Bagriacik et al., 1996) . For B cell maturation, conversion of high-mannose type to complex-type N-linked glycans is essential since treatment with the aforementioned inhibitors blocked production of immunoglobulin (Tulp et al., 1986) . Anti-tumor activity of natural killer cells was reduced by treatment with inhibitors of N-and O-glycosylation (Voshol et al., 1996) . On the other side, swainsonine is able to stimulate proliferation of murine lymphocytes (White et al., 1988) . To approach the issue of possibly altered glycosylation in lymphocytes of CDG patients, we studied glycoprotein synthesis and expression of major B lymphocyte differentiation surface antigens on Epstein-Barr virus immortalized B lymphocytes derived from CDGS patients. Since terminal sialylation is a sensitive marker for altered glycosylation as previously demonstrated for transferrin (Jaeken et al., 1984; Yamashita et al., 1993a) , we examined sialoglycan structures defined by monoclonal antibodies. Sialylation patterns of surface glycans and activities of sialyltransferases were also measured in these cells by a new cytometric assay system using enzyme-mediated labeling with fluorescent sialic acid. Sialyltransferase gene expression was investigated by polymerase chain reaction of transcripts of four different sialyltransferases.
Results

Differentiation markers of EBV-transformed CDG-LCL
Lymphocytes derived from peripheral blood of CDGS type I A patients were subjected to transformation by EBV-containing culture supernatants of the marmoset cell line B95-8 as described (Miller and Lippman, 1973) . Transformed B cells grew continuously in vitro as lymphoblastoid cell lines (LCL). In order to closer define their differentiation stage and to screen for possible differences in surface-expressed glycoprotein structures we stained these cell lines in comparison to normal EBV-transformed B cell lines with a panel of mAb against classified lymphocyte differentiation antigens (CD antigens) (Table I) . CDG-LCL resembled normal EBV-transformed LCL with regard to their expression of CD antigens with the exception of two antigens. In contrast to CDG-LCL normal LCL showed weak expression of CD38, a marker for late B cell maturation steps (Tedder et al., 1984) and no expression of the ecto-5′ nucleotidase CD73 (Thompson et al., 1986) . Interestingly, during previous screening of a large series of different established B cell lines, only the myeloma cell line U266 corresponding to the plasma cell stage, was positive for CD73 . Thus, CDG-LCL seem to be characterized by CD73 positivity.
In general most of these glycoprotein CD antigens were expressed in intensities comparable to those in EBV-transformed normal B lymphocytes and leukemic B cell lines.
Complex glycosylation of surface-expressed and secreted glycoproteins in CDG-LCL
In order to investigate the glycosylation process of surface-expressed glycoproteins in CDG-LCL we performed pulse-chase protein labeling of CDG-LCL and normal EBV-transformed B cell lines. After pulse labeling and various chase times, cells were lysed and the MHC class I glycoprotein was immunoprecipitated. High-mannose type N-linked oligosaccharide chains were cleaved by treatment with endoglycosidases H and F, complex type N-linked glycans by treatment with endoglycosidase F. As can been seen in Figure 1 , complex glycosylation was almost complete during 60-120 min of chase in both cell lines tested since endoglycosidase H treatment became ineffective after these times.
Similar pulse-chase experiments were performed by immunoprecipitation of the µ-chain of IgM. No apparent differences were found in the IgM glycosylation of CDG-LCL in comparison to other B cell lines (data not shown). Further both, CDG-LCL and normal EBV-transformed B cells, secreted complex glycosylated IgM ( Figure 1B ). 
Surface sialylation of CDG-LCL
In order to look at surface sialylation of CDG-LCL we used two different mAb, HH2 of CDw75 and HD66 of CDw76, which recognize α2,6 sialylated lactosaminyl groups Gross et al., 1996) . CDw76 specific mAb differ from CDw75 specific mAb in that they preferentially bind to polylactosaminyl groups expressed on glycosphingolipids . No difference in the expression of both epitopes was detected between CDG-LCL and other B cell lines (Table II) . Negative control cell line MED-B1, which synthesizes ST6GAL I at a very reduced level, does not express these epitopes. Pretreatment of cells with VCN abrogated expression of CDw75 and CDw76 on CDG-LCL as was the case for other B cell lines . We examined the expression of CD77 which is a molecular structure defining the carbohydrate sequence of the globo-series glycosphingolipid Gb 3 (Schwartz-Albiez et al., 1990) . Expression of CD77 on B cell lines is moderate in contrast to native tonsillar B lymphocytes. No conclusive difference in the CD77 expression of CDG-LCL compared to other B cell lines was observed.
MAb 1B2 reacts with a subgroup of lactosaminyl groups (Young et al., 1991) . Sialylation of these sugar sequences masks the epitope . MAb 1B2 bound to CDG-LCL in slightly stronger intensity as compared to normal LCL. As expected from previous experiments, VCN treatment of the cells led to increased binding of 1B2. Therefore, CDG-LCL not only expressed higher amounts of the unsialylated but also of the sialylated 1B2 epitope (Figure 2) . Surprisingly, in CDG-LCL a considerable extent of the 1B2 epitope was sialylated in α2,3 (2) was measured by pulse-chase labeling with [ 35 S]-methionine. Cells were pulsed for 10 min followed by a chase of approximately 12 h. Culture supernatants were harvested, separated from free [ 35 S]-methionine by gel filtration over a PD10 column (Pharmacia, Uppsala, Sweden), reduced in volume by Amicon membrane filtration and subjected to immunoprecipitation with mAb NMZ88.5 against the human Ig µ chain. Immunoprecipitates were enzyme-treated as described for (A), followed by SDS-PAGE and autoradiography.
linkage. This was shown by NDVN-pretreatment of stained cells which resulted in stronger antibody binding than in normal LCL.
We next screened for possible differences in overall surface sialylation of CDG-LCL as compared to other B cell lines. To this end we applied an enzymatic fluorescent labeling technique of cell surface glycans on live cells. The cells were incubated in the presence of CMP-5-F-Neu and exogenous ST6GAL I with or without sialidase pretreatment. Incorporation of fluorescent neuraminic acid into surface glycans was monitored by flow cytometry ( Figure 3A ). Sialylation was measured over a period of 4 h. As shown for CDG-LCL1 in comparison to cell line MED-B1, without sialidase pretreatment the sialylation rate was higher in MED-B1 than in CDG-LCL1 cells. This indicates that MED-B1 cells expressed more nonsialylated sites than CDG-LCL1. However, after VCN pretreatment which effectively cleaves off sialic acid residues in α2,6, α2,3, and α2,8 linkage, the extent of resialylation was higher in CDG-LCL1 than in MED-B1. Therefore, CDG-LCL1 apparently has more glycan sites overall for sialylation. The difference in incorporation of fluorescent neuraminic acid using exogenous ST6GAL I before and after VCN pretreatment indicates the relative degree of natural surface sialylation of lactosaminyl sites. In our example, CDG-LCL1 cells contained more sialylation sites than MED-B1 cells. Incorporation of fluorescent label after VCN treatment observed in MED-B1 cells may be caused by resialylation of previously α2,3 sialylated sites.
In a further step we measured incorporation of fluorescent neuraminic acid with and without VCN-and NDVN pretreatment into the three CDG-LCL and the two normal LCL ( Figure 3B ). No major differences were detected in surface-expressed free lactosaminyl sites whereas the amount of total lactosaminyl sites was larger in normal LCL than in CDG-LCL as revealed by VCN-pretreatment. We conclude that normal LCL contain larger amounts of surface-expressed sialolactosaminyl sites than CDG-LCL. The ratio of incorporation between VCN-treated to untreated cells was not significantly increased in CoxSort and PLH. After NDVN treatment, which preferentially cleaves sialic acids in α2,3 linkage, incorporation of label was less elevated than after VCN-treatment in CoxSort and PLH as compared to CDG-LCL. This result indicates that in normal LCL the larger portion of surface-expressed sialolactosaminyl sites is α2,6 sialylated.
In order to further screen for differences in α 2,6 sialylated surface glycans, we applied a soluble CD22-immunoglobulin fusion protein (CD22Rg) in flow cytometry. CD22 has been Comparison of sialylated and nonsialylated surface-expressed lactosaminyl sequences on CDG-LCL. Cells were incubated in the presence of CMP-5-F-Neu and rat-liver derived ST6GAL I for 4 h. Incorporation of fluorescent neuraminic acid into cell surface glycoconjugates was determined by flow cytometry. Cells were either treated with VCN or NDVN prior to the labeling procedure or were labeled without sialidase pretreatment. Values for fluorescence are given as mean fluorescence intensity/cell. Mean fluorescence intensity was determined in two independent experiments in which the variation of the two absolute values was less than 10%. Free lactosaminyl residues (free LacN) were assessed by staining of untreated cells; total lactosaminyl residues (total LacN) were assessed by staining of VCN-treated cells; α2,6 sialylated residues (α2,6 NeuAc) were assessed by subtracting results of NDVN-treated cells from those of VCN-treated cells; α2,3 sialylated residues (α2,3NeuAc) were assessed by subtracting results of untreated cells from those of NDVN-treated cells.
characterized as a B cell-specific adhesion protein and a member of the I-type class of lectins which recognizes α2,6 sialylated lactosamines (Powell et al., 1993; Sgroi et al., 1993; Powell and Varki, 1995) . As shown in Table IV , all three CDG-LCL bound less of the CD22Rg construct than normal LCL, CoxSort and PLH. VCN-pretreatment of cells abrogated binding of CD22Rg proving the sialoglycan-reactivity of CD22. 
Sialyltransferase activity of CDG-LCL
Intracellular sialyltransferase activity of B cell lines was measured by incorporation of fluorescent neuraminic acid into various acceptor glycoproteins. No significant differences in sialyltransferase activity were detected between CDG-LCL and other EBV-B cells regardless of whether acceptors representative for N-linked (asialo-α1-glycoprotein, asialofetuin) or O-linked oligosaccharides (asialomucin) were taken (Table III) . As an exception, cell line MED-B1 only showed background values for sialylation of N-linked and no measurable activity for O-linked glycans. The defect of sialyltransferase activity in this cell line apparently is at the translational level since transcription of ST6GAL I could be detected by RT-PCR using specific primer for various sialyltransferases as shown below.
To investigate expression of various sialyltransferases at the RNA level we performed RT-PCR using specific primers for four different sialyltransferase genes (Figure 4) . With the exception of MED-B1, all cell lines displayed strong expression of ST6GAL I and a much weaker expression of ST3GAL III and ST3GAL I. Only leukemic cell lines JOK-1 and Raji showed stronger expression of ST3GAL III. Amplified signals for ST3GAL IV cDNA were also present in all eight cell lines, albeit in different intensities. No major differences in expression of sialyltransferase genes could be detected between CDG-LCL and normal EBV-transformed B cell lines. Therefore, CGD-LCL do not differ in their regulation of sialyltransferases from normal EBV-transformed B cells and, consequently, the different expression of sialoglycans in CDG-LCL is not caused by alteration in sialyltransferase activities.
In a previous study, we demonstrated that B cell lines produce a surface-expressed α2,6 ecto-sialyltransferase (Gross et al., 1996) . To test for ecto-sialyltransferase activity we performed surface sialylation with CMP-5-F-Neu in the absence of exogenous sialyltransferase. As depicted in Figure 5 , all three CDG-LCL expressed ecto-sialyltransferase activity which became more apparent after VCN pretreatment of the cells. In accordance with the results shown in Figure 3B , cell line PLH expressed larger amounts of resialylated glycans than CDG-LCL.
Discussion
The aim of this study was to clarify whether cellular glycoproteins of lymphocytes derived from CDGS type I A patients are affected by the disease. To this end we immortalized B lymphocytes of the peripheral blood of CDGS type I A patients by transformation with the Epstein-Barr virus. Lymphoblastoid cell lines received by this method correspond to advanced stages of mature B cells. Using a panel of mAb against relevant B cell differentiation antigens (CD antigens), we showed that the three cell lines of CDGS patients expressed patterns of CD antigens typical for EBV-transformed LCL. As an exception, the GPI-anchored CD73 antigen was present on CDG-LCL but not on normal EBV-transformed LCL and most established B cell lines investigated. Antibody reactivity demonstrated that most of these glycoprotein CD structures typical for B cells were present on CDGS-derived B lymphocytes. However, most of the respective CD mAb recognize protein epitopes. Thus, these antibody reactivities do not provide sufficient information about a possibly altered glycosylation of the respective surface structures. Major defects in glycosylation as for instance impairment of glycan transfer to potential glycosylation sites of the protein, should result in an altered molecular mass of the molecule. To address this issue we immunoprecipitated the surface-expressed MHC class I antigen from CDG-LCL after pulse-chase labeling. No differences in the molecular size were observed as compared to MHC class I molecules precipitated from other B cell lines. In an earlier study we characterized the highly glycosylated B cell differentiation antigen CD37 which carries three potential sites for N-glycosylation (Schwartz-Albiez et al., 1988) . We now precipitated the CD37 antigen from CDG-LCL with a molecular size (64 kDa) equivalent to a CD37 molecule with three N-linked oligosaccharide chains (data not shown). Also, as demonstrated by endoglycosidase F treatment, MHC class I and secreted IgM contained complex glycosylated oligosaccharide chains comparable to those of other B cell lines.
These results are in accordance to those of Powell et al., 1994 , who found that fibroblasts derived from CDGS patients do not differ from fibroblasts of normal persons in their carbohydrate composition and oligosaccharide structures. In another study it was postulated that, although cotranslational glycosylation in CDGS fibroblasts was normal, glycoprotein transport of the hemagglutinin of influenza virus along the secretory pathway was delayed (Marquardt et al., 1995) . In our study using similar methods we could not observe different processing of surface-expressed MHC class I glycoprotein or secreted IgM when pulse-chase labeled molecules were immunoprecipitated and subjected to differential endoglycosidase treatment. The overall glycosylation process of endogenous B cell glycoproteins in CDG-LCL is indistinguishable from that in normal LCL using these methods.
In order to look for differences in the fine structure of sialylated molecules we applied a group of monoclonal antibodies against carbohydrate epitopes (cf. Table II) . Antibodies against CDw75 and CDw76 recognize α2,6 sialylated glycan epitopes . Since these surface epitopes were stained in intensities comparable to other B cell lines, diminished expression of these structures could be excluded. However, CDG-LCL showed stronger staining with mAb 1B2 which recognizes a group of lactosaminyl sequences unmasked by sialic acid (Gross et al., 1996) . Differences to normal EBV-transformed B cells became even more evident when cell surfaces of live cells were pretreated with NDVN, specific for α2,3 linked sialic acid. Increased staining after NDVN treatment indicates enhanced occurrence of the 1B2 epitope masked by α2,3 sialylation on CDG-LCL. In contrast, cell lines CoxSort and PLH surface-expressed the sialylated 1B2 epitopes almost exclusively in α2,6 linkage as deduced from comparative treatment with VCN and NDVN. These results led us to analyze overall sialylation of surface glycans applying a novel assay systems which uses enzyme-mediated surface labeling with fluorescent sialic acid and subsequent flow cytometric analysis. Since we used exogenous ST6GAL I for the transfer of fluorescent sialic acid, surface resialylation was restricted to lactosaminyl sequences. Incorporation of fluorescent neuraminic acid into surface glycans containing free galactose sites did not reveal significant differences between CDG-LCL and normal LCL. Differences between normal and CDG-LCL became obvious after VCN-and NDVN pretreatment. After VCN pretreatment normal LCL incorporated fluorescent sialic acid in larger quantities than the CDG-LCL. CoxSort and PLH contained more α2,6 sialylated lactosaminyl sites than CDG-LCL. We cannot exclude that there is also more α2,8 sialylation in normal LCL, although it seems unlikely that this would influence the extent of overall sialylation since α2,8 sialylation occurs only in a few cell surface-expressed sialoglycans as compared to α2,6 sialoglycans. Indeed, mAb R24 recognizing the α2,8 sialylated GD 3 (Claus et al., 1994) and mAb UM4D4 and F6 against 9-O-acetyl-GD 3 (Vater et al., 1997) were negative on all EBV-transformed B cell lines (data not shown). Strikingly, the ratio between α2,3 and α2,6-linked surface sialoglycans was similar between both types of cell lines with the exception of CDG-LCL3. This observation argues against a disorder of sialyltransferase synthesis in CDG-LCL. In addition, RT-PCR with primers specific for four of the characterized human sialyltransferases (Grundmann et al., 1990; Paulson, 1993, 1994a,b) did not result in any significant and obvious differences in sialyltransferase transcription in CDG-LCL as compared to normal LCL. Furthermore, sialyltransferase activity using three different acceptor molecules was at similar levels in CDG-LCL and normal LCL. Also, CDG-LCL expressed the ecto-sialyltransferase typical for human B lymphocytes (Gross et al., 1996) . Therefore, we conclude that CDG-LCL do not carry an obvious defect in sialyltransferases. Diminished surface expression of α2,6 sialylated glycans in CDG-LCL may be caused by a different availability of lactosaminyl core structures. On the other side, CDG-LCL expressed larger quantities of the α2,3 sialylated 1B2 epitope than normal LCL. It is established from sialyltransferase fine specificity that within the group of lactosaminyl oligosaccharides there are sequences which favor α2,3 instead of α2,6 sialylation. Preference for α2,3 sialylation is largely influenced by branching of lactosaminyl sequences. It was found that the ST3GAL III is less sensitive to structural variations than the ST6GAL I (Nemansky et al., 1995) . In particular, ST6GAL I favors the Galβ1→4GlcNAcβ1→2Man α1→3 branch to the Galβ1→4GlcNAcβ1→2Manα1→6 branch in bi-and triantennary structures (Joziasse et al., 1987) . Therefore, specific sialylation patterns are directed by variations in the oligosaccharide core structures. It may also be that the protein backbone influences sialylation because ST3GAL III displays a 20-fold larger preference for intact glycoproteins in comparison to ST6GAL I which also accepts smaller glycopeptides (Yeh and Cummings, 1997) .
The diminished surface expression of α2,6 sialylated glycans in CDG-LCL was further corroborated by a weaker binding of CD22Rg which specifically reacts with α2,6 sialoglycans. Since CD22 is a B cell-specific adhesion protein which mediates interactions between B cells , diminished expression of CD22 ligands may have implications for the maturation process of B lymphocytes in these patients.
Decreased activity of phosphomannomutase which was found in lymphocytes of CDG 1A patients (Jaeken et al., 1997) may affect in a not yet clearly understood way the antennary structure of lactosaminyl sequences. Strikingly, other effects predicted by this severe enzymatic defect of early glycosylation were apparently absent in cellular glycoproteins of CDG-LCL. For instance, we observed for the CD37 glycoprotein that all three N-glycosylation sites were glycosylated. Also, a possible failure in the synthesis of glycosylphosphatidylinositol (GPI)-protein anchors was not found. CD24 and CD73 representing GPI-anchored surface glycoproteins were present in CDG-LCL. Moreover, binding of CD24 specific antibodies was significantly reduced by treatment of these cells with phosphatidylinositol phospholipase C (PI-PLC, EC 3.1.4.10) proving that CD24 is GPI-anchored in CDG-LCL (data not presented).
CDG-LCL carry subtle deviations in their lactosaminyl structures which only became obvious by sensitive assays for the detection of sialoglycans. Diminished surface expression of α2,6 sialylated glycans in CDG-LCL was observed by three independent assays: CDG-LCL showed (1) reduced labeling with fluorescent neuraminic acid after VCN-pretreatment, (2) weaker binding of the CD22Rg, and (3) lower amounts of glycans resialylated by ecto-sialyltransferase activity.
These differences became apparent in comparison to other EBV-transformed LCL and leukemic B cell lines. Therefore, EBV immortalization of the CDG-LCL does not seem to induce the observed effects which may also be characteristic features of native B lymphocytes of CDGS patients.
Similar to CDGS defects noticed by different appearance of sialylated serum glycoproteins we conclude that also cellular and, in particular surface expressed glycoproteins are affected in cells of CDGS patients. Whether these deviations influence the biological activity of immune cells in CDGS patients remains to be elucidated.
Materials and methods
Materials
All chemicals used were of analytical grade and purchased from Merck (Darmstadt, Germany) or Sigma (St. Louis, MO). 2,3-Dehydro-NeuAc, Vibrio cholerae neuraminidase (VCN; EC 3.2.1.18), Newcastle disease virus neuraminidase (NDVN; EC 3.2.1.18), and ST6GAL I (Galβ1,4GlcNAcα2,6ST, EC 2.4.99.1, from rat liver) were obtained from Boehringer Mannheim (Mannheim, Germany). CMP-NeuAc, CMP-5-F-Neu (cytidine-5′-monophospho-5-fluoresceinthioureido-N-acetyl-neuraminic acid) was prepared enzymatically (CMP contamination in each preparation < 5%) as described previously (Brossmer and Gross, 1994) . Sephadex G50 fine was from Pharmacia (Uppsala, Sweden). Desialylation of glycoproteins was performed by acid hydrolysis as described (Gross et al., 1996) .
Immunoreagents
CD ("cluster of differentiation") and unclustered mAb used for characterization of CDG-LCL cell lines were obtained from the Fourth and Fifth International Workshop on Human Leucocyte Differentiation Antigens (Moldenhauer and Schwartz-Abiez, 1989; Schwartz-Albiez and Moldenhauer, 1989; Schwartz-Albiez et al., 1995) . The CDw75 mAb HH2 was a kind gift of Dr. S. Funderud (Norwegian Radium Hospital, Oslo, Norway), CDw76 mAb HD66 was produced in our laboratory. The mAb 1B2 (Young et al., 1991) was produced using the respective hybridoma 1B2-1B7 obtained from the American Tissue Culture Collection (Rockville, MD). All mAbs against carbohydrate epitopes were of IgM isotype. For immunoprecipitation studies we used mAb W6/32 against the human HLA class I molecule (Barnstable et al., 1978) and mAb NMZ88.5 against the human µ Ig chain (van Endert and Moldenhauer, 1992) .
CD22Rg-specific cDNA was kindly provided by Dr. I. Stamenkovic, Harvard Medical School, Boston.
Cell lines
All cell lines used were of B lymphocyte origin. For this study, we established three new CDGS-cell lines (CDG-LCL1, CDG-LCL2, CDG-LCL3) applying the EBV-transformation technique as described (Miller and Lippman, 1973) . For EBV-transformation we used culture supernatants of the marmoset EBV-leukocyte cell line B95-8 provided by the ATCC (Bethesda, MD). The CDGS cells were derived from peripheral blood of three patients (2-9 years old) who were diagnosed via isoelectrofocusing of serum transferrin to suffer from CDGS type I and found to be phosphomannomutase deficient. For each child patient informed consent of parents was obtained. Peripheral blood lymphocytes from one CDGS type I A patient for the establishment of CDG-LCL were kindly provided by Dr. P. Lorenz, Kinderzentrum Dresden, Germany. After transformation, "lymphoblastoid cell lines" (LCL) were cultivated in Iscove's modified Dulbecco's medium containing 10 % fetal calf serum, 10 mM Hepes, 2 mM l-glutamine, penicillin (100 U/ml), and streptomycin (100 µg/ml). Cell lines CoxSort and PLH derived from EBV-transformed normal peripheral blood B lymphocytes, Burkitts lymphoma cell line Raji and cell line JOK-1 derived from peripheral blood of a patient with hairy cell leukemia were kindly provided by Dr. G. Moldenhauer, German Cancer Research Center, Heidelberg, Germany. The cell line MED-B1 derived from a male patient with mediastinal B cell lymphoma was raised in the laboratory of one of us (P.M.) and was described previously (Ebeling et al., 1996) . Non-CDG-LCL cell lines were cultivated in RPMI 1640 medium containing 10% fetal calf serum, 10 mM Hepes, 2 mM l-glutamine, penicillin (100 U/ml), and streptomycin (100 µg/ml).
Methods
Flow cytometric analysis of B cell differentiation antigens.
Indirect immunofluorescence staining of B cell surface antigens was performed as previously described (Schwartz-Albiez et al., 1991) . As second antibody we used goat anti-mouse IgG and IgM (Fab) 2 antibody conjugated to FITC (Dianova, Hamburg, Germany). As negative control we used the irrelevant mAb HD20. Samples were measured in a FACScan flow cytometer (Becton Dickinson, Mountain View, CA). Dead cells were excluded by staining with propidium iodide.
Flow cytometric detection of cell surface sialylation. Cytometric detection of surface sialylation by endogenous, extracellular sialyltransferase and exogenous sialyltransferase of rat liver was performed as previously described (Bollheimer et al., 1995; Gross et al., 1996) . In brief, the cells were washed with PBS and then treated with or without VCN (5 mU/1 × 10 6 cells/100 µl PBS) or NDVN (2 mU/1 × 10 6 cells/100 µl PBS) for 30 min at 37_C. Enyzmatic reaction was stopped by addition of ice-cold PBS followed by extensive washing in PBS. Then, cells were incubated for times indicated at 37_C with the addition of CMP-5-F-Neu at 25 µΛ and ST6GAL I of rat liver (50 mU/ml) in the presence of 250 µM 2,3 dehydro-2-deoxy-N-acetylneuraminic acid as inhibitor for sialidase activity. In some experiments we tested for endogenous, surface-expressed ecto-sialyltransferase. To this end, exogenous rat liver sialyltransferase was omitted from the experiment (Gross et al., 1996) . Enzymatic activity was stopped by addition of ice-cold PBS and three times washing in PBS. In control experiments, resialylation was performed in the presence of 12 mM CTP in order to competitively inhibit sialyltransferase activity. Viability of cells was not affected by enzymatic treatment as monitored by incorporation of propidium iodide in flow cytometry. For cytometric analysis, cells were washed twice and the cell pellet was resuspended in RPMI 1640 medium containing 1 µg/ml propidium iodide. Green fluorescence of 1 × 10 4 viable cells was analyzed by excluding dead cells identified by red fluorescence (propidium iodide label). Fluorescence intensity was determined as the mean fluorescence of fluorescent NeuAc/stained cell. Background fluorescence levels were defined as the fluorescence of cells incubated at 0_C with fluorescent CMP-glycosides or incubated at 37_C in the presence of CTP.
Sialoglycan-specific mAb CDw75, CDw76, and CD77 mAb as well as mAb 1B2 were applied in flow cytometry as described above. The cDNA specific for CD22Rg was integrated into the immunoglobulin expression vector pIg (Simmons, 1993) and was introduced into COS cells by the DEAE-dextran method as described elsewhere . CD22Rg contains the first three immunoglobulin-like domains of CD22 linked to the Fc part of IgG1. CD22Rg was purified from COS transfectant culture supernatants by chromatography on protein A-Sepharose 4B.
For flow cytometry CD22Rg was preincubated with goat anti-human IgG1 (Fc-specific) coupled to biotin in equimolar concentrations (5 µg/ml) for 1 h at room temperature. The complex was applied to VCN-pretreated and untreated cells for 30 min on ice. Reactivity of CD22Rg was detected by incubation with streptavidin coupled to FITC. Cells were incubated with goat immunoglobulin (100 µg/ml) for 10 min at room temperature before the specific staining procedure, followed by two washing steps with PBS containing 1% bovine serum albumin. As negative controls we used human IgG1 (5 µg/ml) precomplexed with goat anti-human IgG1 (Fc-specific) and further staining as described above. As positive control we applied mAb W6/32 directed against MHC class I.
Fluorometric determination of sialyltransferase activity. For determination of intracellular sialyltransferase activity, 5 × 10 6 cells were incubated in 200 µl lysis buffer, consisting of PBS and 0.5% NP40, for 60 min on ice. The lysates were centrifuged for 10 min at 800 × g, and subsequently for 15 min at 10,000 × g. The supernatant of this centrifugation step was taken for measurement of sialyltransferase activity. As acceptors we used asialofetuin (3 mg/ml), asialo-α 1 -acid glycoprotein (1.6 mg/ml), and asialomucin (3 mg/ml). The standard reaction mixture contained 62.5 mM sodium-cacodylate, 0.1 % Triton X-100, and 25 mM CMP-5-F-Neu as donor in a total volume of 20 µl. The reaction was started by addition of 5 µl of cellular lysates. The reaction was stopped after 20 min by addition of 3.7 µl 0.1 M CTP. For controls, corresponding enzymatic reactions were run in the presence of the same concentration of CTP. The fluorescence incorporated into glycoprotein acceptors was determined using liquid chromatography (Gross et al., 1996) . for the indicated chase times. Cells were harvested, washed twice in PBS, and lysed in PBS containing 1% Nonidet P-40 and protease inhibitors (10 mM PMSF, 20 mU/ml aprotinin) for 20 min at 0_C. Nuclei and cellular debris was removed by centrifugation at 1500 × g. For detection of secreted proteins, culture supernatants were further processed after 10 min pulse with [ 35 S]-methionine/cysteine and centrifugation of the cells. To remove free [ 35 S]-amino acids, the culture supernatant was applied to a PD 10 gel filtration column (Pharmacia, Uppsala, Sweden) according to the manufacturers instructions. The void volume of the column containing protein-bound radioactivity was further reduced in volume by passage over a concentration filter membrane (B15, Amicon, Beverly, MA). Cell lysates and culture supernatants were then cleared by two pre-adsorptions using protein A-Sepharose CL-4B (Pharmacia) to reduce nonspecific binding. For immunoprecipitation, [ 35 S]-labeled proteins were mixed with 10 µg of purified monoclonal antibody and 20 µl protein A-Sepharose CL-4B (50% suspension in PBS). After overnight incubation at 4_C under gentle rotation, the immunoprecipitates were washed extensively and then boiled in SDSsample buffer containing dithiothreitol. Samples were subjected to SDS-PAGE and radioactive bands were visualized by exposure to x-ray films. Immunoprecipitates were treated with either endoglycosidase H or F (EC 3.2.1.96; Schwartz-Albiez et al., 1991) .
Radiolabeling of cells, immunoprecipitation
RNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR).
To analyze transcription of sialyltransferases in CDG-LCL we performed reverse transcriptase polymerase chain reaction (RT-PCR) of four different sialyltransferase sequences. Total RNA from the cell lines was prepared using the Trizol reagent from Gibco (Paisley, UK) according to the manufacturers protocol. Two µg of total RNA were reverse transcribed into cDNA by oligo (dT) priming using the Superscript kit (Gibco). Specific primers were chosen within the open reading frame of the respective cDNA sequences. A common PCR program was used for all amplifications: 30 cycles with 1 min 20 s at 95_C, 1 min 20 s at 60_C, 1 min at 72_C, 2 s extension. Of each forward (F) and reverse (R) primer 200 ng were used in a total volume of 100 µl. Primers were derived from published cDNA sequences. For the ST6GAL I (Grundmann et al., 1990) primers were designed as follows: F (5′-CTCTGAATTC-CTCCCAACTAGGC-3′) with positions 1006-1028, R (5′-GATGGGAGGAACTCATAAATATCC-3′) with positions 1468-1445, for the ST3GAL III (Kitagawa and Paulson, 1993) we used F (5′-CTCCAATTCAGTGGTTCTTTCC-3′) with positions 114-135 and R (5′-AAGGGTAGGGATGTTCCCC-3′) with positions 906-888, for the ST3GAL I (Kitagawa and Paulson, 1994b) we applied F (5′-CTTCCTGAACTACTCCCA-CACC-3′) with positions 1002-1023 and R (5′-TGCAGC-CAGTTGTCAAAGAC-3′) with positions 1712-1693, for the ST3GAL IV (Kitagawa and Paulson, 1994a) we used F (5′-TGAGGATCTGCTCCTCCG-3′) with positions 276-293 and R (5′-CAGAAGGACGTGAGGTTCTTG-3) with positions 998-978. As internal control for gene expression, human β-actin-specific primers (Stratagene, Heidelberg, Germany) were used for parallel RT-PCR amplifications. The two primers produced a 661 bp fragment.
Aliquots of 20 µl of the amplification product were analyzed by electrophoresis on 1% agarose gels containing ethidium bromide. 
